Investment Thesis — Moderna, Inc.
Moderna is misunderstood as a one-hit COVID wonder, but its mRNA platform is on the cusp of commercializing multiple vaccines and therapeutics, positioning the company for a second act. The market is overly discounting near-term losses and pipeline risk, ignoring the potential for rapid revenue diversification and margin recovery.
Catalysts
- RSV vaccine FDA approval and launch
- Positive Phase 3 data from flu or oncology pipeline
- Strategic partnership or M&A activity leveraging mRNA platform
Risk Factors
- Pipeline clinical trial failures
- Regulatory setbacks or delays
- Rapid erosion of COVID vaccine revenues without replacement
Key Debates
RSV vaccine drives revenue growth above 15% by H2 2024
Short squeeze pushes MRNA above $70 by Q3 2024
MRNA valuation reverts to analyst target of $35.67 by Q4 2024